Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist
Top Cited Papers
- 1 November 2001
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 358 (9295) , 1754-1759
- https://doi.org/10.1016/s0140-6736(01)06844-1
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist PegvisomantNew England Journal of Medicine, 2000
- Efficacy and Tolerability of the Long-Acting Somatostatin Analog Lanreotide in Acromegaly. A 12-Month Multicenter Study of 58 Acromegalic PatientsPituitary, 2000
- The Human Growth Hormone Antagonist B2036 Does Not Interact with the Prolactin ReceptorEndocrinology, 1999
- Results of a European Multicentre Study with Sandostatin® LAR® in Acromegalic PatientsPituitary, 1999
- Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegalyJournal of Neurosurgery, 1998
- Cabergoline in the Treatment of Acromegaly: A Study in 64 PatientsJournal of Clinical Endocrinology & Metabolism, 1998
- The Role of Radiotherapy in AcromegalyJournal of Clinical Endocrinology & Metabolism, 1997
- Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.Journal of Clinical Endocrinology & Metabolism, 1995
- Rational Design of Potent Antagonists to the Human Growth Hormone ReceptorScience, 1992
- Long-term Treatment of 189 Acromegalic Patients With the Somatostatin Analog OctreotideArchives of internal medicine (1960), 1991